Cytokine traps: multi-component, high-affinity blockers of cytokine action
Aris N. Economides(Regeneron (United States)), Neil Stahl(Regeneron (United States)), Thomas J. Daly(Regeneron (United States)), Vivien Wong(Regeneron (United States)), Laura Rocco Carpenter(Regeneron (United States)), Jennifer McNay(Regeneron (United States)), Scott Carver(Regeneron (United States)), James P. Fandl(Regeneron (United States)), Renta Hutabarat(Alnylam Pharmaceuticals (United States)), Swayampakula Ramakanth(Regeneron (United States)), Erica Pyles(Regeneron (United States)), George D. Yancopoulos(Regeneron (United States)), Xiaobing Xu(Changhai Hospital), Frank Lee(Regeneron (United States)), Kevin M. Bailey(Regeneron (United States)), Michael Young(Regeneron (United States)), Czeslaw Radziejewski(Regeneron (United States)), John S. Rudge(MedStar Washington Hospital Center), Christopher Hartnett(Regeneron (United States)), Ellen Koehler-Stec(Regeneron (United States)), Tammy Huang(Regeneron (United States))
Cited by 361
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k
Angiopoietin-1 protects the adult vasculature against plasma leakage
|Nature Medicine|2000|1.3k
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
|New England Journal of Medicine|2013|961